Exact Sciences (EXAS) Misses Q1 EPS by 1c, Revs Beat; Raises Outlook

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.66), $0.01 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $162 million versus the consensus estimate of $153.04 million.

GUIDANCE:

Exact Sciences sees FY2019 revenue of $725-740 million, versus prior of $710-$730 million the consensus of $729.5 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Taylor Devices (TAYD) Misses Q4 EPS by 31c